Paper Details

  1. Home
  2. Paper Details

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Author: AntonarakisEmmanuel S, BeerTomasz M, CarducciMichael, ChenIyah, DeVilleCurtiland, DeWeeseTheodore L, DeekMatthew P, DenmeadeSam, DesaiNeil B, EisenbergerMario, GaverMatt, GrecoStephen, HearnJason W, HeathElisabeth I, HungArthur Y, KapoorRoche, KummerloweMegan, LiauwStanley, LotanTamara, MarkowskiMark, McIntyreRiley, PallerChanning, RamanNatasha, SongDaniel Y, SprattDaniel E, TranPhuoc T, WangHao

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This trial studies the effectiveness of salvage radiation therapy (SRT) combined with enzalutamide, a next-generation selective androgen receptor antagonist, for the treatment of rising PSA following radical prostatectomy. The primary objective is to evaluate the efficacy of the combination for freedom-from-PSA-progression.
Paper Details　
Original Abstract of the Article :
In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associated higher rates of treatment side effects. This trial studies the effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567492/

データ提供：米国国立医学図書館（NLM）

Salvage Radiation Therapy and Enzalutamide: A New Approach for Prostate Cancer

The battle against prostate cancer requires a multi-pronged approach, often combining different therapies to optimize outcomes. This study investigates the efficacy of salvage radiation therapy (SRT) combined with enzalutamide, a potent anti-androgen, in men with rising PSA levels following radical prostatectomy. The researchers aimed to evaluate the effectiveness of this combination in delaying PSA progression and controlling tumor growth.

Exploring New Frontiers in Prostate Cancer Treatment

The study is currently underway, investigating the potential benefits of combining SRT with enzalutamide for men with high-risk PSA-recurrent prostate cancer. The researchers aim to determine the impact of this combination on freedom-from-PSA-progression, time to local recurrence, metastasis-free survival, and overall safety. This research holds promise for advancing treatment strategies and improving patient outcomes in the management of prostate cancer.

A Journey Towards Enhanced Treatment Options

The study underscores the importance of exploring new and innovative approaches to treating prostate cancer. By investigating the efficacy of SRT combined with enzalutamide, this research could lead to the development of more effective and personalized treatment strategies for men with this disease. This highlights the ongoing evolution of prostate cancer therapy and the commitment to improving patient care.

Dr.Camel's Conclusion

This research exemplifies the continuous pursuit of improved treatment options for prostate cancer. By exploring the potential benefits of SRT combined with enzalutamide, this study represents a significant step forward in the quest to combat this challenging disease. The desert of prostate cancer research is vast and complex, but ongoing exploration and innovation offer hope for a brighter future for those facing this diagnosis.
Date :
  1. Date Completed 2019-12-23
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31196032

DOI: Digital Object Identifier

PMC6567492

Related Literature

Article Analysis
・Side Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.